​

Charles River Laboratories (CRL) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

CRL Stock Forecast

Charles River Laboratories (CRL) stock forecast, based on 32 Wall Street analysts, predicts a 12-month average price target of $303.60, with a high of $465.00 and a low of $151.00. This represents a 186.28% increase from the last price of $106.05.

$100 $180 $260 $340 $420 $500 High: $465 Avg: $303.6 Low: $151 Last Closed Price: $106.05

CRL Stock Rating

Charles River Laboratories stock's rating consensus is Buy, based on 32 Wall Street analysts. The breakdown includes 1 Strong Buy (3.12%), 16 Buy (50.00%), 15 Hold (46.88%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 32 15 16 1 Strong Sell Sell Hold Buy Strong Buy

CRL Price Target Upside V Benchmarks

TypeNameUpside
StockCharles River Laboratories186.28%
SectorHealthcare Stocks 35.25%
IndustryDiagnostics & Research Stocks46.62%

Price Target Trends

1M3M12M
# Anlaysts--8
Avg Price Target--$228.75
Last Closing Price$106.05$106.05$106.05
Upside/Downside--115.70%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 2521161-20
Mar, 2532142-21
Feb, 2523122120
Jan, 2534123123
Dec, 2434123-22
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 15, 2024Luke SergottBarclays$205.00$193.146.14%93.31%
Oct 14, 2024Jamie ClarkRedburn Partners$151.00$192.97-21.75%42.39%
Sep 17, 2024Ann HynesMizuho Securities$210.00$206.441.72%98.02%
Aug 08, 2024Justin BowersDeutsche Bank$240.00$200.3419.80%126.31%
Jul 10, 2024Eric ColdwellRobert W. Baird$239.00$201.8518.40%125.37%
Jun 28, 2024Luke SergottBarclays$230.00$207.3510.92%116.88%
Jun 06, 2024Matthew SykesGoldman Sachs$290.00$216.1234.18%173.46%
May 09, 2024Elizabeth AndersonEvercore ISI$265.00$230.0915.17%149.88%
Apr 01, 2024Elizabeth AndersonEvercore ISI$300.00$270.9510.72%182.89%
May 05, 2022Donald HookerKeyBanc$300.00$257.5116.50%182.89%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 04, 2025CitigroupSellNeutralupgrade
Oct 23, 2024CLSAUnderperforminitialise
Oct 15, 2024BarclaysEqual-WeightEqual-Weighthold
Oct 01, 2024CitigroupBuySelldowngrade
Aug 08, 2024Deutsche BankBuyBuyhold
Jun 27, 2024BarclaysEqual-Weightinitialise
Jun 06, 2024Goldman SachsBuyinitialise
May 13, 2024Cowen & Co.HoldHoldhold
May 09, 2024Evercore ISIOutperformOutperformhold
Apr 01, 2024Evercore ISIOutperformOutperformhold

Financial Forecast

EPS Forecast

$7 $8 $9 $10 $11 $12 $13 $14 $15 $16 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$7.35$7.77$9.57$9.27-----
Avg Forecast$7.86$10.26$10.89$10.59$10.19$9.88$11.00$12.43$14.23
High Forecast$8.05$10.51$11.15$10.68$10.30$12.56$12.63$15.07$15.26
Low Forecast$7.63$9.96$10.70$10.45$10.12$9.10$9.71$10.39$13.52
Surprise %-6.49%-24.27%-12.12%-12.46%-----

Revenue Forecast

$3B $3B $4B $4B $5B $5B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$2.92B$3.54B$3.98B$4.13B$4.05B----
Avg Forecast$2.89B$3.52B$3.91B$4.11B$4.03B$3.93B$4.16B$4.37B$4.63B
High Forecast$2.94B$3.59B$3.98B$4.12B$4.05B$4.07B$4.18B$4.42B$4.89B
Low Forecast$2.82B$3.44B$3.86B$4.10B$4.02B$3.77B$4.15B$4.31B$4.46B
Surprise %1.18%0.50%1.64%0.55%0.47%----

Net Income Forecast

$50M $200M $350M $500M $650M $800M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$364.30M$390.98M$486.23M$474.62M$93.11M----
Avg Forecast$285.53M$364.08M$454.69M$474.62M$525.43M$557.17M$574.85M$654.91M$732.15M
High Forecast$342.63M$436.89M$545.62M$569.55M$530.07M$646.04M$650.02M$775.34M$785.01M
Low Forecast$228.42M$291.26M$363.75M$379.70M$520.79M$468.30M$499.69M$534.47M$695.76M
Surprise %27.59%7.39%6.94%--82.28%----

CRL Forecast FAQ

Is Charles River Laboratories stock a buy?

Charles River Laboratories stock has a consensus rating of Buy, based on 32 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 16 Buy, 15 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Charles River Laboratories is a favorable investment for most analysts.

What is Charles River Laboratories's price target?

Charles River Laboratories's price target, set by 32 Wall Street analysts, averages $303.6 over the next 12 months. The price target range spans from $151 at the low end to $465 at the high end, suggesting a potential 186.28% change from the previous closing price of $106.05.

How does Charles River Laboratories stock forecast compare to its benchmarks?

Charles River Laboratories's stock forecast shows a 186.28% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and outperforming the diagnostics & research stocks industry (46.62%).

What is the breakdown of analyst ratings for Charles River Laboratories over the past three months?

  • April 2025: 10.00% Strong Buy, 5.00% Buy, 80.00% Hold, 5.00% Sell, 0% Strong Sell.
  • March 2025: 14.29% Strong Buy, 9.52% Buy, 66.67% Hold, 9.52% Sell, 0% Strong Sell.
  • February 2025: 10.00% Strong Buy, 15.00% Buy, 60.00% Hold, 10.00% Sell, 5.00% Strong Sell.

What is Charles River Laboratories’s EPS forecast?

Charles River Laboratories's average annual EPS forecast for its fiscal year ending in December 2025 is $9.88, marking a 0% decrease from the reported $0 in 2024. Estimates for the following years are $11 in 2026, $12.43 in 2027, and $14.23 in 2028.

What is Charles River Laboratories’s revenue forecast?

Charles River Laboratories's average annual revenue forecast for its fiscal year ending in December 2025 is $3.93B, reflecting a -3.02% decrease from the reported $4.05B in 2024. The forecast for 2026 is $4.16B, followed by $4.37B for 2027, and $4.63B for 2028.

What is Charles River Laboratories’s net income forecast?

Charles River Laboratories's net income forecast for the fiscal year ending in December 2025 stands at $557.17M, representing an 498.37% increase from the reported $93.11M in 2024. Projections indicate $574.85M in 2026, $654.91M in 2027, and $732.15M in 2028.